Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content

Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00476879

Enrollment

Registered

2007-05-22

Start date

2006-08-31

Completion date

2008-06-30

Last updated

2008-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver, Metabolism

Keywords

Growth hormone, Fasting, Signaltransduction, fatty liver, insulin sensitivity, forearm model, protein metabolism, respiratory quotient

Brief summary

The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.

Detailed description

During fasting the human body is known to metabolize relatively large amounts of fat, in the expense of proteins and glucose. Partly this shift in metabolism is caused by increasing GH secretion, but exactly how growth hormone exerts these effects remains to be further investigated. 10 healthy lean young men are studied at 4 different occasions in a randomized single-blinded cross-over study. 1: after 12 hours of fasting + GH bolus, 2: after 36 hours of fasting + GH bolus, 3: after 36 hours + saline, 4: after 36 hours of fasting + Somavert. Aim: * to study the signal transduction in muscle and fat tissue * to study the metabolism during fasting * to study the intrahepatic fat content using magnetic resonance techniques

Interventions

DRUGSomatropin and pegvisomant

Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* male * healthy * age 20 - 40 years of age * BMI 20 -25

Exclusion criteria

* uses any medication * drinks more than 21 units of alcohol per * is claustrophobic * carries any magnetic devices

Design outcomes

Primary

Measure	Time frame
forearm metabolism	36 hours of fasting
changes in respiratory quotient	36 hours of fasting
metabolism	36 hours of fasting
insulin sensitivity	36 hours of fasting
changes in intrahepatic lipid content	12 and 36 hours of fasting. respectively
changes in intracellular signaling during fasting	36 hours

Secondary

Measure	Time frame
Changes in grelin	36 hours of fasting
changes in leptin, adiponektin, cortisol, catecholamine, glucagon, carbamide, palmitate	36 hours of fasting
changes in FFA	36 hours of fasting

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026